Lophius Biosciences GmbH Appoints Dr. Robert Phelps As Director Business Operations

Lophius Biosciences GmbH Appoints Dr. Robert Phelps As Director Business Operations

 

Regensburg, Germany, December 4, 2013 / B3C newswire / – Lophius Biosciences GmbH, a privately held biotech company developing and marketing innovative T cell-based diagnostic systems for the early diagnosis and immunomonitoring, today announced that Dr. Robert Phelps has joined the Company as Director Business Operations.

Dr. Phelps has more than thirteen years successful international experiences in business development and licensing in the biotech and pharma industry. Lastly, he has been Head of Business Development & Licensing at SuppreMol GmbH in Munich, where he was responsible for all business development and licensing activities relating to the company's clinical drug development candidates. Previous to that, he has held business development and licensing positions at various biotechnology and pharmaceutical companies. Dr. Phelps received his PhD in biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany, held a research position as a post-doctoral fellow at the Medical University of South Carolina, Charleston (SC), USA, and holds the Certified Licensing Professional (CLP) credentials. "With his longstanding experience in business development and licensing, we are happy that we were able to get Robert on board" said Prof. Ralf Wagner, Managing Director of Lophius Biosciences. "He is a valuable addition to our team and will be instrumental in supporting our efforts to exploit the excellent development and marketing opportunities for our T cell-based diagnostic systems such as T-Track® CMV."

"I am very happy to join Lophius," Dr. Phelps added. "The Company has been highly successful in transforming their T cell monitoring platform technologies into viable products enabling doctors to individually adjust prophylactic and immunosuppressive therapy e.g. during solid organ and bone marrow transplantation to the benefit of patients. I am extremely impressed by the potential of their platform technologies and their deep product pipeline."

About Lophius Biosciences

Lophius Biosciences GmbH, a German biotech company, is focusing on the development and marketing of innovative T-cell based diagnostic systems for diagnosis and immunomonitoring. The Company's first product is T-Track® CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo a immunosuppressive therapy. With its innovative products, the Company aims to significantly improve therapy control and personalized treatment of patients in the area of transplantation medicine, infectious and autoimmune diseases.

Contact

Dr. Robert Phelps

Director Business Operations

Lophius Biosciences GmbH

Tel: +49 (0)941 6309197-80

[email protected]

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.